Press Detail

/
PRESS RELEASE

Biotest AG and Affibody AB enter into a Research License and Option Agreement regarding the Albumod(TM) technology platform

- Affibody's Albumod(TM) technology is designed to prolong the duration of action of biopharmaceuticals and therefore potentially enhances the efficacy of biopharmaceuticals

Dreieich, Germany and Solna, Sweden, 1 June 2015. Biotest AG and Affibody AB today announce that the companies have signed a research license and option agreement.

The agreement relates to Affibody's proprietary Albumod(TM) technology in relationship with compounds of Biotest portfolio. The technology is designed to enhance the efficacy of biopharmaceuticals e.g. by prolonging the period of effectiveness of such compounds.

"We believe that Affibody's Albumod^TM technology has great potential for the development of improved protein drugs in Biotest's therapeutic areas for example hemophilia" says Dr. Jörg Schüttrumpf, Senior Vice President Global Research Biotest.

Affibody will receive up-front and milestone payments. Upon opt-in after the research phase Biotest will receive exclusive rights for clinical testing and commercialisation. After market launch royalties on sales for licensing of the Albumod(TM) platform will be paid. Further details of the agreement have not been disclosed.
The research project is in preclinical stage.

About the Albumod(TM) platform
Affibody's Albumod(TM) technology is designed to enhance the efficacy of biopharmaceuticals by extending their circulatory half-life, thereby allowing for less frequent dosing and lower peak concentrations in blood with a decreased risk for adverse events. In addition to these patient safety benefits, the overall treatment costs could be reduced.
For more information please refer to: www.affibody.se.

About Affibody AB
Affibody AB is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody^(R) molecules and Albumod(TM). Affibody is developing a portfolio of innovative drug projects and in addition, offers the half-life extension technology, Albumod(TM) for outlicensing.

Affibody has ongoing commercial relationships with several companies including Algeta, Amylin, Daewoong, Daiichi Sankyo, Swedish Orphan Biovitrum, GE, Nordic Nanovector, and Thermo Fisher.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has more than 2.100 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.